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Objective: In 1991, researchers reported that a modest preovulatory increase in serum progesterone
levels is associated with lower pregnancy rates and higher incidence of pregnancy loss in in vitro
fertilization (IVF). We wonder whether embryo transfer (ET) in assisted reproductive technology (ART)
cycles in patients with premature progesterone rise (PPR) have a negative impact on the clinical preg-
nancy rates (CPRs) and/or live birth rates (LBRs) in our series. Consequently, will blastocyst transfer
reverse the negative impact?
Materials and methods: This noninterventional, retrospective, observational tertiary center study was
conducted between January 2010 and December 2012. All fresh ET cycles with serum progesterone levels
measured (n ¼ 599) on the day of hCG administration were analyzed.
Results: Sera lutenizing hormone (LH), E2, and progesterone (P) were measured and analyzed. The CPRs
of cycles in patients with p  1.5 ng/mL (low) versus those with p > 1.5 ng/mL (high) were 37.04% versus
41.03% [odds ratio (OR) ¼ 1.18, 95% conﬁdence interval (CI): 0.728e1.920; p ¼ 0.50). The LBRs of cycles in
patients with low progesterone level versus those with PPR were 30.52% versus 34.62% (OR ¼ 1.21, 95%
CI: 0.729e1.992; p ¼ 0.47). No statistically signiﬁcant association was detected. We further analyzed the
outcomes according to different stages of ET and found that blastocyst (D5) ET signiﬁcantly increase the
LBRs as compared with cleavage stage (D2/D3) ET in the PPR group (44.44% versus 21.43%; p ¼ 0.043).
Conclusion: PPR did not signiﬁcantly compromise the clinical outcomes in this series. However, shifting
to blastocyst transfer probably could increase the live birth in cycles with PPR.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Many researchers have adopted the term “premature proges-
terone rise (PPR)” or “premature luteinization (PL)” for patients
with progesterone elevation on the day of human chorionic
gonadotropin (hCG) administration for ﬁnal oocyte maturation [1].
In 1991, Schoolcraft et al [2] and Silverberg et al [3] reported that and Gynecology and Women's
aiwan Boulevard, Section 4,
J. Chen).
for this article.
bstetrics & Gynecology. Publishedmodest preovulatory increase in serum progesterone levels was
associated with lower pregnancy rates and higher incidence of
pregnancy loss in ovarian stimulation for in vitro fertilization (IVF),
but the pathogenesis and effects of PPR or PL on IVF outcomes
remain controversial.
Several authors have failed to demonstrate any negative impact
of PPR on assisted reproductive technology (ART) outcomes [4e10]
while others reported that pregnancy rates [11e13] or live birth
rates [14] have been inversely related to serum progesterone levels
or duration of elevation [15] on the day of hCG administration.
Furthermore, Ou et al [16] suggested that ovarian response or
reserve may be of critical importance when considering PL or PPR.by Elsevier Taiwan LLC. All rights reserved.
Table 1
Characteristics of patients with different serum progesterone levels on hCG day.
Progesterone level
(ng/mL)a
1.5 (N ¼ 521) >1.5 (N ¼ 78) p
Age (y) 35.36 (4.61) 34.19 (3.70) 0.02*






9.92 (1.66) 10.26 (1.52) 0.1










rFSH/LH dosage ratio 3.44 (2.85) 3.78 (2.25) 0.004**







P/E2 ratio 0.84 (1.35) 2.78 (5.05) <0.0001**
Number of oocytes
retrieved
10.45 (7.50) 11.10 (7.22) 0.37
No. of pronucleus cells 6.60 (4.87) 10.73 (7.21) <0.0001**
No. of embryos
transferred
2.86 (0.96) 2.91 (1.00) 0.65
Data are presented as %/% or mean (standard deviation).
*p < 0.005.
**p < 0.001.
BMI ¼ body mass index; E2 ¼ XXX; HCG ¼ human chorionic gonadotropin;
IU ¼ international unit; LH ¼ lutenizing hormone; P ¼ ; rFSH ¼ recombinant follicle
stimulating hormone.
a ManneWhitney U test and Chi-square test (Fisher's test) were used for statis-
tical analyses as appropriate.
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had no adverse effect on pregnancy rates in fresh embryo-transfer
cycles within different ovarian responses.
Papanikolaou et al [17] and Ochsenkühn et al [14] concluded
that blastocyst transfer (D5) was more effective than early
cleavage-stage embryo transfer (D2/D3) for improving pregnancy
rates and live birth rates.
The purpose of the present study is to review from our own
series the impacts of premature elevated serum progesterone levels
on the pregnancy outcomes of fresh embryo transfer cycles. We
alsowanted to ﬁnd out whether the ovarian responses play a role in
these phenomena. Furthermore, we retrospectively investigated
whether D5 blastocyst transfer (D5-ET) could improve the clinical




This noninterventional, retrospective, observational tertiary
center study, which enrolled women treated for infertility, was
conducted in the Center for Reproductive Medicine of Taichung
Veterans General Hospital, Taichung, Taiwan between January 2010
and December 2012.
Participants
A total of 777 cycles undergoing assisted reproduction [in vitro
fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI)]
with controlled ovarian hyperstimulation (COH), suppression of
premature ovulation by GnRH agonists [leuprolide acetate or trip-
torelin acetate (50.08%)], antagonists [cetrotide (34.06%)] or other
protocols [including mild stimulation, natural cycle, or modiﬁed
natural cycle (15.86%)], were included for chart review in the study
period. As we did not routinely check preovulatory progesterone
levels until August 2010, there were 69 cycles excluded initially. We
also excluded cases (109 cycles) which did not receive fresh embryo
transfers (ET). We included 27 cycles of cancelled oocyte retrieval,
24 cycles of fertilization failure, 10 cycles of very poor embryos
development, 31 cycles of planned oocytes and/or embryos cryo-
preservation, and 17 cycles of postponement for ET due to very high
serum E2 (>8000 pg/mL) and/or risk of ovarian hyperstimulation
syndrome. Finally a total of 599 nonselective fresh ET cycles with
serum progesterone levels measured on the day of hCG injection
were analyzed.
The mean age of patients was 35.21 years (range, 23e49 years).
The primary or combined indications for fertility treatment were
male subfertility (29.33%), tubal pathology (24.52%), endometriosis
(15.63%), polycystic ovarian syndrome (PCOS; 2.40%), adenomyosis
(1.68%) and other causes (0.48%), including malignancy or immu-
nology. Detailed patient characteristics with different progesterone
levels are listed in Table 1.
All patients signed awritten informed consent document for the
ART treatment. Institutional Review Board approval was not
mandatory, because all women in the study underwent the routine
IVF/ICSI-ET clinical treatment performed in our unit and no addi-
tional intervention or blood sampling was performed.
Controlled ovarian hyperstimulation protocol
Brieﬂy, patients in the GnRH agonist group received either leu-
prolide acetate (Leuprolide, 0.1 mg/d; Famar L'Aigle) or triptorelin
acetate (Decapeptyl SR, 0.1 mg/d; Ipsen Pharmaceuticals, Ltd.),
consisting of a daily low dose of GnRHa, subcutaneouslyadministrated for at least 10 days before the onset of ovarian
stimulation. However, participants in the antagonist group received
the GnRH antagonist cetrorelix acetate (Cetrotide, 0.25 mg/
d SC; Merck Serono) starting ﬂexibly on stimulation Days 5e7
by ultrasound monitoring 5 days after the onset of COH with
gonadotrophins.
The types and dosages of gonadotropin administration were
individualized by the attending physician for each participant ac-
cording to her age, body mass index, antimullerian hormone level,
follicle-stimulating hormone (FSH) level/antral follicle counts on
cycle Days 2e3 and previous response to ovarian stimulation. Doses
were adjusted according to ovarian response as monitored by
means of vaginal ultrasound folliculometry and serum E2 level
testing.
When two or more follicles reached a mean diameter of 18 mm,
10,000 IU of hCG (Pregnyl; Organon) or 500 ug of recombinant hCG
(Ovidrel; Merck-Serono) was injected for the oocyte retrieval
35e36 hours later. Progesterone 25mg/amp,1e2 amp/d (Astar Co.),
was injected intramuscularly starting from the day of oocyte
retrieval and continued or shifted to topical progesterone (Crinone;
Merck-Serono) 1 tube/d on the day of embryo transfer, then
maintained until the day of serum b-hCG check-up (14 days after
ovum pick-up) for luteal support (LS). In cases of ICSI treatment,
0.1 mg Decapetyl was also administered 6 days after ICSI as a
measure of additional luteal support. If pregnancy was conﬁrmed,
LS was maintained until gestational Week 8. The embryo transfers
were carried out on Day 2, Day 3, or Day 5 of culture.Hormone assays
Sera were obtained on the day of hCG administration for oocyte
retrieval; lutenizing hormone (LH), E2, and progesterone (P) were
measured and analyzed by Immulite 2000 (Euro Diagnostic Prod-
ucts Corporation, Ltd.). The intra- and interassay coefﬁcients of
variation, respectively, were 3.71% and 6.2% for LH, 4.9% and 7.1% for
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0.2 ng/mL and the range of measurement was 0.2e40 ng/mL.
Patients were ﬁrst categorized into ﬁve different groups ac-
cording to serum progesterone levels as follows: 0.5 ng/mL,
0.5001e1.0 ng/mL, 1.001e1.5 ng/mL, 1.5001e2.0 ng/mL, and >2 ng/
mL and the pregnancy outcomes of each group were analyzed.
Then patients were further categorized into two serum proges-
terone levels: 1.5 ng/mL (low) versus >1.5 ng/mL (high),
according to the cutoff value reported from the previous literature.
The clinical pregnancy and live birth rates were statistically
compared according to the day of embryo transfer (D2/D3 and
D5 ET).
Outcomes measurement
The serum b-hCG was measured 14e16 days following oocyte
retrieval and was checked as necessary. When the gestational sac
was detected by transvaginal ultrasonographic evaluation at
gestational Week 5, it indicated the clinical pregnancy. Further-
more, we followed all the on-going pregnancies until live delivery,
which indicated live birth.
Grouping of poor, intermediate, and high ovarian responders
We categorized ovarian responses into three arbitrary groups
according to the number of oocytes retrieved [12]: poor ovarian
response (4 oocytes retrieved), intermediate ovarian response
(5e19 oocytes retrieved), and high ovarian response (20 oocytes
retrieved). We explored the relationship between serum proges-
terone levels on the day of hCG administration and the IVF out-
comes in different ovarian responders.
Statistical analysis
Analyses were performed using SPSS (version 15.1; SPSS Inc.,
Chicago, IL, USA). ManneWhitney U test, Chi-square test (Fisher's
test) and logistic regression were used for statistical analyses as
appropriate. The signiﬁcance level was set at p < 0.05.
Results
The CPRs in each progesterone level group (0.5 ng/mL,
0.5001e1.0 ng/mL, 1.001e1.5 ng/mL, 1.5001e2.0 ng/mL, and >2 ng/
mL) were 35.71% (45/126), 34.13% (86/252), 43.36% (62/143),
40.91% (18/44), and 41.18% (14/34), respectively. The LBRs in each
progesterone level group were 30.95% (39/126), 25.79% (65/252),
38.47% (55/143), 31.82% (14/44), and 38.24% (13/34), respectively.
There were no statistically signiﬁcant differences in CPRs and LBRs
among the ﬁve groups in our series (p ¼ 0.42 and p ¼ 0.10,
respectively).
In all patients, serum progesterone levels on the day of hCG
administration ranged from 0.2 ng/mL to 14.30 ng/mL. Patients
were assigned to Group 1 [1.5 ng/mL (low)] or Group 2 [>1.5 ng/
mL (high)] based on the serum progesterone values. Statistical
distribution of the progesterone levels in Group 1 was as follows:
mean, 0.78 ng/mL; standard deviation, 0.34 ng/mL; maximum,
1.50 ng/mL; 25th percentile, 0.51 ng/mL; 50th percentile, 0.76 ng/
mL; and 75th percentile, 1.03 ng/mL. Statistical distribution of the
progesterone levels in Group 2 was as follows: mean, 2.34 ng/mL;
standard deviation, 1.66 ng/mL; maximum, 14.30 ng/mL; 25th
percentile, 1.71 ng/mL; 50th percentile, 1.93 ng/mL; and 75th
percentile, 2.30 ng/mL (p < 0.001). Group 2 were considered to
show a premature progesterone rise.
The total incidence of PPR in our cycles was 13.02%. Based on
different treatment protocols, the incidences of PPR were 18.00%(54/300) in the GnRH agonist subgroup, 9.31% (19/204) in the GnRH
antagonist subgroup and 5.26% (5/95) in the other protocols sub-
group. There were no statistically signiﬁcant differences in PPR
incidence between the antagonist subgroup and the other pro-
tocols subgroup (p ¼ 0.3312). However, the PPR incidence of the
agonist subgroup was signiﬁcantly higher than that of the antag-
onist and the other protocols subgroups (p ¼ 0.01 and p ¼ 0.004,
respectively).
Female and male infertility status, mean number of stimulation
days, total dose of administered recombinant follicle stimulating
hormone (rFSH) and LH, serum E2 level, number of retrieved
oocytes, and number of transferred embryos did not differ between
these two progesterone-level groups (Table 1). However, the
mean age of Group 2 patients was lower than that of Group 1
patients (35.36 years vs. 34.19 years, respectively, correlation
coefﬁcient:0.080; p < 0.05). Furthermore, the gonadotropin rFSH/
LH ratio, the number of pronucleus cells (2PN) and the P/E2 ratio in
Group 2 were signiﬁcantly increased. Progesterone level on the day
of hCG administration was positively and signiﬁcantly correlated
with the number of pronucleus cells (correlation coefﬁcient: 0.197;
p < 0.001) and the P/E2 ratio (correlation coefﬁcient: 0.481;
p < 0.001).
The mean number of transferred embryos was similar in both
groups, 2.86 versus 2.91, respectively. The CPRs of the low pro-
gesterone group versus that of the high progesterone group was
37.04% versus 41.03%, respectively [odds ratio (OR) ¼ 1.18, 95%,
conﬁdence interval (CI): 0.728e1.920; p ¼ 0.50]. The LBRs of the
low progesterone group versus that of the high progesterone group
was 30.52% versus 34.62%, respectively (OR ¼ 1.21, 95%, CI:
0.729e1.992; p ¼ 0.47). No statistically signiﬁcant association be-
tween progesterone elevation and the probability of CPRs or LBRs
was detected (Table 2).
We further analyzed the ART outcomes according to the
different treatment protocols (Table 2). However, no statistical
signiﬁcance was found both in CPRs and LBRs within different
protocols.
Moreover, we analyzed our results according to the ovarian
responses (Table 3). In the poor responder subgroup, the CPRs of
the low progesterone group versus that of the high progesterone
group was 23.62% versus 22.22%; the LBRs of the two groups were
18.90% versus 16.67%, respectively, and neither group reached
statistical signiﬁcance. The results were similar, and without sta-
tistical signiﬁcance, in both the intermediate and high responder
subgroups.
According to our data, 69 cycles received blastocyst (D5) transfer
instead of early cleavage stage (D2 or D3) embryo transfer (Table 4).
We also analyzed the basal characteristics in patients with PPR, and
found these two groups (D2/D3 ET versus D5 ET with PPR) pre-
sented similar baseline characteristics such as mean patient age
(34.67 vs. 33.30, p ¼ 0.315), rates of mature oocytes (76% vs. 79%,
p ¼ 0.987), fertilization rates (65% vs. 71%, p ¼ 0.361), and rates of
good quality embryos (81% vs. 69%, p ¼ 0.626). Here, embryo
quality was evaluated and those cleavage stage embryos with four
cells in Day 2 or from six to eight cells in Day 3 with equal size of
blastomere/without fragmentation (Grade 1) and allowing for up to
20% fragmentation (Grade 2) were qualiﬁed as good-quality em-
bryos. Furthermore, we used a Gardner's blastocyst scoring system
with the blastocysts better than 3AB or 3BA deﬁned as good-quality
embryos. The CPRs of D2/D3 ET versus that of D5 ET was 35.29%
versus 51.85% in PPR group (p ¼ 0.157). However, D5 ET could
signiﬁcantly increase the LBRs in the PPR group as compared with
D2/D3 ET (44.44% vs. 21.43%, p < 0.05). There were two cases, on D5
ET, in which a pregnancy failed to carry to term in the PPR group.
One of them was an ectopic pregnancy and the other was a missed
abortion at gestation Week 10.
Table 2
Assisted reproductive technology outcomes grouped by controlled ovarian hyperstimulation protocols.a
Progesterone level (ng/mL) 1.5 >1.5 p Odds ratio (95% CI)
GnRH agonist (N ¼ 300)
Clinical pregnancy ratesb 34.96 (86/246) 40.74 (22/54) 0.52 1.28 (0.700e2.337)
Live birth ratesc 27.24 (67/246) 35.19 (19/54) 0.32 1.45 (0.776e2.710)
GnRH antagonist (N ¼ 204)
Clinical pregnancy rates 41.62 (77/185) 47.37 (9/19) 0.81 1.26 (0.490e3.254)
Live birth rates 35.68 (66/185) 36.84 (7/19) 1.00 1.05 (0.395e2.801)
Other protocolsd (N ¼ 95)
Clinical pregnancy rates 33.33 (30/90) 20 (1/5) 1.00 0.50 (0.054e4.672)
Live birth rates 28.89 (26/90) 20 (1/5) 1.00 0.62 (0.066e5.770)
Total (N ¼ 599)
Clinical pregnancy rates 37.04 (193/521) 41.03 (32/78) 0.50 1.18 (0.728e1.920)
Live birth rates 30.52 (159/521) 34.62 (27/78) 0.47 1.21 (0.729e1992)
Data are presented as % (n/N).
*p < 0.05.
**p < 0.001.
CI ¼ conﬁdence interval; GnRH ¼ gonadotropin-releasing hormone.
a Chi-square test (Fisher's exact test) and Logistic regression were used for statistical analyses as appropriate.
b Clinical pregnancy rates (CPRs) were deﬁned as the appearance of gestational sac as revealed by transvaginal ultrasonography.
c Live birth rates (LBRs) were deﬁned as live delivery.
d Other protocols group included participants who received controlled ovarian hyperstimulation with mild stimulation, natural cycle or modiﬁed natural cycle.
Table 3
Assisted reproductive technology outcomes grouped by different ovarian responses.a
Progesterone level (ng/mL) 1.5 >1.5 p Odds ratio (95% CI)
Oocytes retrieved  4 (N ¼ 145)
Clinical pregnancy ratesb 23.62 (30/127) 22.22 (4/18) >0.99 0.92 (0.283e3.019)
Live birth ratesc 18.90 (24/127) 16.67 (3/18) >0.99 0.86 (0.230e3.203)
5 Oocytes retrieved  19 (N ¼ 372)
Clinical pregnancy rates 40.56 (131/323) 44.90 (22/49) 0.67 1.19 (0.652e2.187)
Live birth rates 32.2 (104/323) 36.73 (18/49) 0.64 1.22 (0.654e2.286)
Oocytes retrieved  20 (N ¼ 82)
Clinical pregnancy rates 45.07 (32/71) 54.55 (6/11) 0.79 1.46 (0.408e5.237)
Live birth rates 43.66 (31/71) 54.55 (6/11) 0.53 1.55 (0.432e5.547)
Data are presented as % (n/N).
*p < 0.05.
**p < 0.001.
CI ¼ conﬁdence interval.
a Chi-square test (Fisher's exact test) and Logistic regression were used for statistical analyses as appropriate.
b Clinical pregnancy rates (CPRs) were deﬁned as the appearance of gestational sac as revealed by transvaginal ultrasonography.
c Live birth rates (LBRs) were deﬁned as live delivery.
P.-C. Huang et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 641e646644Discussion
The deﬁnition of premature luteinization (PL) or premature
progesterone rise (PPR) differed and was believed to be responsible
for the variable pregnancy outcome assessment in previously
published literature. Most studies used an absolute progesteroneTable 4
Assisted reproductive technology outcomes according to different embryo transfer
days.a
Progesterone level (ng/mL) D2/D3 ET D5 ET p
Clinical pregnancy ratesb
1.5 37.58 (180/479) 30.95 (13/42) 0.394
>1.5 35.29 (18/51) 51.85 (14/27) 0.157
Live birth ratesc
1.5 31.32 (150/479) 21.43 (9/42) 0.780
>1.5 29.41 (15/51) 44.44 (12/27) 0.043*
Data are presented as % (n/N).
*p < 0.05.
D2/D3 ET ¼ early cleavage-stage embryo transfer; D5 ET ¼ blastocyst embryo
transfer.
a Chi-square test (Fisher's exact test) was used for statistical analyses as
appropriate.
b Clinical pregnancy rates (CPRs) were deﬁned as the appearance of gestational
sac as revealed by transvaginal ultrasonography.
c Live birth rates (LBRs) were deﬁned as live delivery.level on the day of hCG administration as an indicator of PPR, and
the cut-off values ranged from 0.8 ng/mL to 2 ng/mL [5e7,18,19]. In
recently published studies, which used new methods of serum
progesterone assessment, this cut-off concentrationwas usually set
at 1.5 ng/mL [20]. The selection of this cut-off is supported by ev-
idence showing a marked difference in endometrial gene expres-
sion proﬁles between patients with a serum progesterone
concentration above and below the threshold of 1.5 ng/mL on the
day of hCG administration [20,21].
Recently, Ou et al [16] suggested that ovarian response or reserve
may be of critical importance when considering PPR. More follicles
produce more serum progesterone. Therefore, Younis et al [22]
deﬁned PPR as a P/E2 ratio >1. This criterion could differentiate be-
tween the progesterone level secretion from immature follicles and
the physiologic secretion from multiple healthy mature follicles [1].
There is a marked variation in the incidence of PPR due to dis-
crepancies in deﬁnition, population characteristics, and/or treat-
ment protocols among studies. The reported incidence of PPR
varies from 13% to 71%, when an absolute progesterone level is used
to deﬁne PPR. The incidence of PPR using the criterion of P/E2 ratio
>1 was 41% in the report by Younis et al [22]. It should be noted that
the proportion of patients with progesterone elevation varies
widely even among studies in which the same serum progesterone
threshold and the same type of GnRH agonist were chosen.
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dencewas 18.00% in the GnRH agonist subgroup, 9.31% in the GnRH
antagonist subgroup, and 5.26% in the other protocols subgroup. By
comparison, the incidences of a progesterone rise >1.5 ng/mL were
24.1% and 23.0% in the agonist and antagonist groups, respectively,
in the study by Papanikolaou et al [13]. The discrepancies between
our series and that study were probably due to the use of a different
gonadotropin or GnRH analogue, different population characteris-
tics and different sample sizes (n ¼ 599 in our series vs. n ¼ 190 in
the study by Papanikolaou et al [13]).
Since the early 1990s, the impacts of PPR on ART outcomes have
remained controversial [23,24]. Several authors have failed to
demonstrate any negative impact of this rise on ART outcomes
[4e10], while others reported that pregnancy rates were inversely
associated with serum progesterone concentrations on the day of
hCG administration [3,11,25e27].
In an attempt to resolve this controversy, Venetis et al [28]
conducted a meta-analysis of published studies (5 studies; 700
patients). In this meta-analysis, a lower pregnancy rate was found
in patients with elevated progesterone on the day of hCG admin-
istration; however, no statistically signiﬁcant association between
progesterone elevation and the probability of clinical pregnancy
was detected (OR ¼ 0.75, 95% CI: 0.53e1.06; p ¼ 0.10).
In a subsequent meta-analysis, regarding the impact of proges-
terone on GnRH antagonist cycles alone (5 studies; 585 patients),
progesterone elevation on the day of hCG administration was
signiﬁcantly associated with a lower probability of clinical preg-
nancy (9%, 95% CI 17e2%, ﬁxed model effects; p < 0.02) [29].
Following their previous meta-analysis, Venetis et al [30] con-
ducted a more comprehensive systemic review and published a
meta-analysis in 2013, which evaluated 63 studies (n ¼ 55,199
cycles) in fresh IVF cycles over a range of progesterone elevation
thresholds (0.4e3.0 ng/mL). They concluded that progesterone di-
minishes the probability that women undergoing fresh IVF cycles
will achieve pregnancy, even at concentrations in the range of
0.8e1.1 ng/mL (OR ¼ 0.79), and this likelihood appears to be
increased when the progesterone concentration reaches
1.2e1.4 ng/mL (OR ¼ 0.67) or higher. Interestingly, this effect ap-
pears to be relatively stable at concentrations >1.2 ng/mL.
In our series, there were no statistically signiﬁcant differences in
IVF/ICSI outcomes, either in CPRs or LBRs, in the 1.5 ng/mL and the
>1.5 ng/mL groups. The differences between our study results and
those of a recent meta-analysis probably were due to the limited
number of patients, the different COH protocols used and the
methods of progesterone measurement in this series. Furthermore,
the younger age of patients in the PPR group in our studymight have
had a positive impact on the IVF/ICSI outcomes. Moreover, the mean
progesterone level was 0.78 ng/mL (n ¼ 521) in our nonPPR group;
according to the meta-analysis of Venetis et al [30], there was a
slightly detrimental effect on ART outcomes at this threshold level.
Although a signiﬁcant inverse relationship between serum
progesterone on the day of hCG administration and the success of
IVF was established in many programs, the involved endocrino-
logical mechanism was unclear. It may involve an ovarian event,
with adverse effects on oocyte maturation, fertilization, or early
cleavage [2,24e26,31]. However, poorer embryo quality was not
reported in other studies [4,7,18,32]. In our series, we did not ﬁnd
adverse effects of PPR on oocyte maturation, number of oocytes
retrieved and fertilization results. These ﬁndings suggested that
PPR may impact the success of IVF, not via an ovarian event, but
through its inﬂuence on the endometrium, possibly leading to
impaired endometrial receptivity. Melo et al [33] retrospectively
analyzed 240 oocyte-donation cycles inwhich 120 women donated
twice, with elevated progesterone levels in the ﬁrst donation cycle
and no progesterone elevation in the following one. The resultsshowed that progesterone elevation did not have a negative impact
on ongoing pregnancy rates. In a study by Xu et al [12], the im-
plantation potential of frozenethaw ET cycles for the embryos
derived from cycles with prematurely elevated progesterone was
not impaired.
In light of these observations, it would be better to take into
account both the ovarian response and the serum progesterone
level when considering the reasons for this phenomenon [1].
Similar to the study by Xu et al [12], our series showed that elevated
progesterone had no negative effect on pregnancy rates in fresh
embryo transfer cycles in all groups with different ovarian re-
sponses (Table 3).
The risk of PPR appears to be associated with the number and
size of follicles and the intensity of FSH stimulation. Elevated pro-
gesterone may lead to embryo/endometrial asynchrony, reducing
the probability of implantation. It might be worth evaluating the
possibility of cryopreserving the resulting embryos and their
transfer in a subsequent frozenethawed cycle [3,18,34] or alter-
natively, administering hCG at an earlier time in the follicular
phase, prior to progesterone elevation [31].
Papanikolaou et al [17] suggested that on the ﬁfth luteal day, the
endometrium has already signiﬁcantly recovered from the
disruption induced by the supraphysiologic progesterone levels.
Using a progesterone cut-off level of 1.5 ng/mL, they found that
elevated progesterone had a signiﬁcant negative effect on the
pregnancy outcome when cleavage-stage embryos were trans-
ferred. However, no negative effect on blastocyst stage transfers
was observed, supporting the idea that the blastocyst transfer
strategy could potentially overcome the detrimental effect of pro-
gesterone elevation.
In 1997, Fanchin et al [23] cocultured embryos up to the blas-
tocyst stage and reported similar blastulation rates in low and high
progesterone groups, but patients in the high progesterone group
had signiﬁcantly lower clinical and ongoing pregnancy rates. Three
other studies reported that fresh D5 blastocyst transfer could not
completely overcome the detrimental effect of elevated proges-
terone levels on IVF/ICSI cycles on the day of hCG administration
[14,35,36]. In a recent meta-regression analysis, Venetis et al [30]
did not ﬁnd evidence of a signiﬁcant moderating effect of the
developmental stage of embryo at transfer (cleavage vs. blastocyst
stage) on the association of progesterone elevation with the prob-
ability of pregnancy achievement, after controlling for the effect of
the progesterone elevation thresholds employed in the various
datasets analyzed (coefﬁcient þ0.28, 95%, CI 0.17e0.74; overall
model: p ¼ 0.15).
In our study, 69 patients received blastocyst transfer (D5 ET)
instead of early cleavage embryo transfer (D2/D3 ET). In the PPR
group, the LBRs were statistical signiﬁcantly decreased by D2/D3,
but not D5, ET (Table 4). Although D5 blastocyst transfer did not
induce any statistically signiﬁcant improvement in the CPRs in the
PPR group, it did signiﬁcantly enhance the LBRs. However, addi-
tional case series are needed to support this ﬁnding.
In conclusion, our analysis of the outcomes of 599 ARTcycles in a
3-year period revealed that PPR did not signiﬁcantly compromise
the clinical outcomes in this series. However, shifting to D5 blas-
tocyst transfer probably could enhance the LBRs in cycles with PPR.
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